DRPLA (Dentatorubral-Pallidoluysian Atrophy)
Introduction
Drpla (Dentatorubral Pallidoluysian Atrophy) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Dentatorubral-Pallidoluysian Atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disorder characterized by progressive cerebellar ataxia, myoclonus, choreoathetosis, and cognitive decline. The disease is caused by an unstable CAG trinucleotide repeat expansion in the ATN1 (Atrophin-1) gene on chromosome 12p13.31. DRPLA belongs to the family of polyglutamine (polyQ) diseases, which also includes Huntington's disease, several spinocerebellar ataxias, and spinal bulbar muscular atrophy (Kennedy's disease) [1](https://pubmed.ncbi.nlm.nih.gov/10803683/). [@progressive]
The clinical phenotype varies significantly with age of onset, which ranges from childhood to late adulthood. Juvenile-onset cases (before age 20) typically present with progressive myoclonus epilepsy (PME) and severe intellectual disability, while adult-onset cases present with ataxia, choreoathetosis, and dementia [2](https://pubmed.ncbi.nlm.nih.gov/12428980/). DRPLA exhibits genetic anticipation, meaning successive generations tend to develop symptoms earlier and more severely, a phenomenon directly correlated with expanding CAG repeat lengths across generations [3](https://pubmed.ncbi.nlm.nih.gov/9521589/). [@trinucleotide]
...DRPLA (Dentatorubral-Pallidoluysian Atrophy)
Introduction
Drpla (Dentatorubral Pallidoluysian Atrophy) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Dentatorubral-Pallidoluysian Atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disorder characterized by progressive cerebellar ataxia, myoclonus, choreoathetosis, and cognitive decline. The disease is caused by an unstable CAG trinucleotide repeat expansion in the ATN1 (Atrophin-1) gene on chromosome 12p13.31. DRPLA belongs to the family of polyglutamine (polyQ) diseases, which also includes Huntington's disease, several spinocerebellar ataxias, and spinal bulbar muscular atrophy (Kennedy's disease) [1](https://pubmed.ncbi.nlm.nih.gov/10803683/). [@progressive]
The clinical phenotype varies significantly with age of onset, which ranges from childhood to late adulthood. Juvenile-onset cases (before age 20) typically present with progressive myoclonus epilepsy (PME) and severe intellectual disability, while adult-onset cases present with ataxia, choreoathetosis, and dementia [2](https://pubmed.ncbi.nlm.nih.gov/12428980/). DRPLA exhibits genetic anticipation, meaning successive generations tend to develop symptoms earlier and more severely, a phenomenon directly correlated with expanding CAG repeat lengths across generations [3](https://pubmed.ncbi.nlm.nih.gov/9521589/). [@trinucleotide]
DRPLA was first described independently by Japanese researchers in the 1970s, and the causative gene was identified in 1994. The disease is particularly prevalent in Japan, where it accounts for approximately 5-10% of all autosomal dominant cerebellar ataxias, but cases have been reported worldwide in various ethnic populations [4](https://pubmed.ncbi.nlm.nih.gov/15156461/). [@longterm]
Genetics
ATN1 Gene
The ATN1 (Atrophin-1) gene encodes a 1,625-amino acid nuclear protein that is widely expressed throughout the body, with highest expression in the brain, particularly in the striatum and cerebellum. The protein contains a polymorphic CAG repeat in exon 5 that, when expanded beyond a pathogenic threshold, results in DRPLA [5](https://pubmed.ncbi.nlm.nih.gov/7920657/). [@kctdrelated]
The normal CAG repeat length in the ATN1 gene ranges from 6 to 35 repeats. Repeats of 36-39 are considered intermediate alleles with reduced penetrance, while repeats of 40 or more are fully penetrant for DRPLA. The repeat length demonstrates a strong inverse correlation with age of onset: juvenile-onset cases typically have 65-88 repeats, while adult-onset cases usually have 48-60 repeats [6](https://pubmed.ncbi.nlm.nih.gov/8608296/). [^6]
Pathogenic Mechanism
The expanded polyglutamine (polyQ) tract in the ATN1 protein leads to neurodegeneration through a toxic gain-of-function mechanism: [^7]
Protein misfolding and aggregation: The expanded polyQ tract causes abnormal protein folding, leading to the formation of intracellular aggregates
Transcriptional dysregulation: Mutant ATN1 interacts with and disrupts the function of transcription factors, including the nuclear receptor co-repressor (N-CoR) complex
Excitotoxicity: Enhanced glutamate excitotoxicity in affected [neurons](/entities/neurons)
Mitochondrial dysfunction: Impaired mitochondrial energy metabolism
[Autophagy](/entities/autophagy)-lysosomal dysfunction: Disrupted protein clearance pathways [7](https://pubmed.ncbi.nlm.nih.gov/19557873/)Inheritance
DRPLA follows autosomal dominant inheritance with high penetrance. Each child of an affected parent has a 50% chance of inheriting the mutant allele. The phenomenon of genetic anticipation is pronounced in DRPLA, with offspring typically developing symptoms 10-20 years earlier than their affected parent. This is explained by meiotic instability of the CAG repeat, particularly during paternal transmission, where repeat expansions are more common than contractions [8](https://pubmed.ncbi.nlm.nih.gov/9521589/). [^8]
Pathophysiology
Neuropathology
The neuropathological hallmarks of DRPLA include: [^9]
- Neuronal loss and atrophy: Progressive degeneration of neurons in the dentatorubral system (dentate nucleus of the cerebellum and red nucleus of the midbrain) and the pallidoluysian system (external segment of the globus pallidus and subthalamic nucleus)
- Atrophin-1 protein accumulation: Intranuclear inclusions containing mutant ATN1 protein with expanded polyQ tracts, most abundant in neurons of the striatum and cerebellum
- White matter degeneration: Involvement of cerebellar white matter and pontocerebellar tracts
- Cerebral atrophy: Progressive cortical and subcortical brain atrophy, particularly in later stages [9](https://pubmed.ncbi.nlm.nih.gov/10441578/)
Affected Brain Regions
The distribution of neurodegeneration in DRPLA correlates with the characteristic clinical features: [^10]
- Dentate nucleus and red nucleus: Degeneration underlies progressive cerebellar ataxia
- Globus pallidus (external segment): Choreoathetosis and dystonia
- Subthalamic nucleus: Movement disorder manifestations
- Cerebral [cortex](/brain-regions/cortex) and subcortical white matter: Cognitive decline and dementia
- Brainstem: Various neurological symptoms including dysphagia and dysarthria [10](https://pubmed.ncbi.nlm.nih.gov/10794881/)
Clinical Manifestations
Juvenile-Onset DRPLA (Age < 20 years)
The juvenile form of DRPLA is characterized by: [^11]
- Progressive myoclonus epilepsy (PME): Intractable myoclonic seizures, often with generalized tonic-clonic seizures
- Severe intellectual disability: Progressive cognitive decline leading to profound dementia
- Myoclonus: Action myoclonus, stimulus-sensitive myoclonus
- Ataxia: Progressive cerebellar ataxia with gait instability
- Chorea and athetosis: Involuntary movements
- Seizures: Often the presenting symptom, with myoclonic seizures being most characteristic [11](https://pubmed.ncbi.nlm.nih.gov/12428980/)
Adult-Onset DRPLA (Age ≥ 20 years)
The adult form presents with: [^12]
- Cerebellar ataxia: Progressive gait and limb ataxia, dysarthria, and nystagmus
- Chorea and athetosis: Involuntary choreiform movements, often beginning in the face and extremities
- Dementia: Subcortical dementia with executive dysfunction, memory impairment, and personality changes
- Myoclonus: Less prominent than in juvenile form
- Psychiatric symptoms: Depression, anxiety, and behavioral changes
- Peripheral neuropathy: Sensorimotor neuropathy in some cases [12](https://pubmed.ncbi.nlm.nih.gov/10803683/)
Disease Progression
DRPLA is relentlessly progressive, with the typical disease duration ranging from 10 to 25 years. The rate of progression correlates with repeat length, with larger expansions associated with more rapid deterioration. Major milestones include: [^13]
Initial symptom onset (ataxia, myoclonus, or seizures)
Loss of independent ambulation (typically 10-15 years after onset)
Severe cognitive impairment
Death, usually from aspiration pneumonia or complications of immobility [13](https://pubmed.ncbi.nlm.nih.gov/15156461/)Diagnosis
Clinical Diagnosis
DRPLA should be suspected in patients presenting with: [^14]
- Progressive cerebellar ataxia
- Myoclonus epilepsy (especially in juveniles)
- Chorea or athetosis
- Cognitive decline/dementia
- Family history of similar symptoms
Genetic Testing
Molecular genetic testing for CAG repeat expansion in the ATN1 gene is the definitive diagnostic test: [^15]
- PCR-based detection of repeat length
- Confirmatory testing for intermediate and reduced penetrance alleles
- Preymptomatic and prenatal testing available for at-risk individuals [14](https://pubmed.ncbi.nlm.nih.gov/7920657/)
Neuroimaging
Brain MRI findings in DRPLA include: [^16]
- Cerebellar atrophy: Prominent atrophy of the cerebellar vermis and hemispheres
- Brainstem atrophy: Particularly of the pontine and medullary regions
- Cerebral atrophy: Cortical and subcortical brain atrophy, progressive over time
- White matter changes: T2/FLAIR hyperintensities in periventricular and subcortical white matter
- Globus pallidus abnormalities: Signal changes in the external segment [15](https://pubmed.ncbi.nlm.nih.gov/10794881/)
Electroencephalography (EEG)
In patients with myoclonus, EEG shows: [^17]
- Generalized spike-wave discharges
- Photosensitivity
- Background slowing with progression
Treatment and Management
Current Therapeutic Approaches
There is currently no cure or disease-modifying therapy for DRPLA. Management is supportive and symptomatic [16](https://pubmed.ncbi.nlm.nih.gov/19557873/):
Antiepileptic Drugs for Myoclonus
- Valproic acid: First-line for myoclonus
- Clonazepam: Adjunctive therapy for myoclonus
- Levetiracetam: Often effective for myoclonus epilepsy
- Perampanel: May be considered for refractory myoclonus
- Avoid sodium channel blockers that may exacerbate myoclonus
Movement Disorder Management
- Tetrabenazine or deutetrabenazine: For chorea
- Botulinum toxin injections: For focal dystonia
- Physical therapy: For gait training and fall prevention
Cognitive and Psychiatric Care
- Acetylcholinesterase inhibitors: May provide modest benefit for cognitive symptoms
- Antidepressants: For depression and anxiety
- Behavioral interventions: For personality changes
Emerging Therapies
Several therapeutic approaches are under investigation:
Gene silencing: Antisense oligonucleotides (ASOs) targeting mutant ATN1 mRNA to reduce toxic protein production
Protein clearance enhancers: Compounds promoting autophagy and [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) function
Transcription modulators: Drugs targeting transcriptional dysregulation
Neuroprotective agents: Compounds aimed at preventing neuronal death [17](https://pubmed.ncbi.nlm.nih.gov/32350456/)Supportive Care
Comprehensive multidisciplinary care is essential:
- Neurological care: Regular monitoring and symptom management
- Physical therapy: Maintaining mobility and function
- Occupational therapy: Adaptive strategies for daily activities
- Speech therapy: For dysarthria and dysphagia
- Nutritional support: Maintaining adequate nutrition, especially as dysphagia progresses
- Psychosocial support: Counseling and support groups for patients and families
See Also
- [Spinocerebellar Ataxias](/diseases/spinocerebellar-ataxia)
- [Huntington's Disease](/mechanisms/huntington-pathway)
- [Kennedy's Disease (SBMA)](/diseases/kennedys-disease)
- [Progressive Myoclonus Epilepsies](/diseases/progressive-myoclonus-epilepsy)
- [Polyglutamine Diseases](/mechanisms/polyglutamine-diseases)
- [Ataxin Proteins](/proteins/ataxin-proteins)
External Links
- [National Institute of Neurological Disorders and Stroke (NINDS)](https://www.ninds.nih.gov/)
- [Genetic and Rare Diseases Information Center - DRPLA](https://rarediseases.info.nih.gov/)
- [Orphanet - DRPLA](https://www.orpha.net/)
- [OMIM: DRPLA](https://www.omim.org/entry/125370)
- [GeneReviews: DRPLA](https://www.ncbi.nlm.nih.gov/books/NBK555725/)
Background
The study of Drpla (Dentatorubral Pallidoluysian Atrophy) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research (2024-2026)
This section highlights recent publications relevant to this disease.
- [Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model.](https://pubmed.ncbi.nlm.nih.gov/41624332/) (2026 Mar 12) - Molecular therapy. Nucleic acids
- [Progressive Myoclonic Epilepsies - A Pragmatic Review.](https://pubmed.ncbi.nlm.nih.gov/41817056/) (2026 Mar 1) - Neurology India
- Trinucleotide repeat disorders.](https://pubmed.ncbi.nlm.nih.gov/41697335/) (2026 Feb 16) - Radiologie (Heidelberg, Germany)
- [Long-term efficacy and disease-specific responsiveness to protirelin in patients with spinocerebellar degeneration: A retrospective study.](https://pubmed.ncbi.nlm.nih.gov/41722180/) (2026 Feb 11) - Parkinsonism & related disorders
- [KCTD7-related progressive myoclonic epilepsy: Clinical and genetic characterization of six Indian patients and review of literature.](https://pubmed.ncbi.nlm.nih.gov/41564653/) (2026 Feb) - Seizure
References